Henry Schein, Inc. (NASDAQ:HSIC - Get Free Report) has received an average rating of "Moderate Buy" from the fourteen brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $93.57.
A number of research firms have recently weighed in on HSIC. Barclays reaffirmed an "overweight" rating and set a $100.00 price objective (up from $86.00) on shares of Henry Schein in a research report on Thursday, August 6th. Piper Sandler increased their target price on shares of Henry Schein from $91.00 to $95.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. UBS Group increased their target price on shares of Henry Schein from $94.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, November 4th. Barrington Research set a $104.00 target price on shares of Henry Schein in a research note on Wednesday, August 5th. Finally, BTIG Research lifted their price target on shares of Henry Schein from $100.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, August 19th.
Check Out Our Latest Stock Analysis on HSIC
Henry Schein Price Performance
Shares of Henry Schein stock opened at $84.96 on Tuesday. The stock has a market cap of $9.39 billion, a P/E ratio of 23.28, a P/E/G ratio of 1.51 and a beta of 0.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.76 and a current ratio of 1.33. The stock's fifty day moving average is $85.81 and its 200 day moving average is $81.59. Henry Schein has a one year low of $68.70 and a one year high of $92.18.
Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.20. The business had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.48 billion. Henry Schein had a return on equity of 16.39% and a net margin of 3.07%. Henry Schein's revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.38 earnings per share. Sell-side analysts anticipate that Henry Schein will post 5.55 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of HSIC. Southpoint Capital Advisors LP raised its holdings in Henry Schein by 28.0% during the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company's stock valued at $235,840,000 after acquiring an additional 700,000 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Henry Schein by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company's stock worth $211,734,000 after acquiring an additional 56,687 shares during the period. M.D. Sass LLC boosted its stake in shares of Henry Schein by 2.9% in the first quarter. M.D. Sass LLC now owns 1,273,316 shares of the company's stock worth $93,843,000 after acquiring an additional 35,443 shares during the period. Bank of America Corp DE grew its position in shares of Henry Schein by 5.9% during the first quarter. Bank of America Corp DE now owns 1,221,585 shares of the company's stock worth $90,031,000 after purchasing an additional 68,593 shares in the last quarter. Finally, Defilade Capital Management L.P. grew its position in shares of Henry Schein by 94.8% during the first quarter. Defilade Capital Management L.P. now owns 624,037 shares of the company's stock worth $45,992,000 after purchasing an additional 303,615 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.
Henry Schein Company Profile
(
Get Free Report)
Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.